Pulmonary Drug Delivery Systems Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Dry Powder Inhalers, Nebulizers, and Metered Dose Inhalers), Indication (Asthma, Chronic

Pulmonary Drug Delivery Systems Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Dry Powder Inhalers, Nebulizers, and Metered Dose Inhalers), Indication (Asthma, Chronic Obstructive Pulmonary Diseases, Cystic Fibrosis, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E-Commerce), End User (Hospitals & Clinics and Homecare), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)

The pulmonary drug delivery systems market size is expected to grow from US$ 49.71 billion in 2023 to US$ 73.14 billion by 2031; the market is projected to register a CAGR of 4.9% during 2023–2031.

Pulmonary drug delivery refers to the technologies and methods used to deliver medications directly into the lungs. These systems are aimed at targeting the delivery of aerosols directly to epithelial cells and respiratory epithelium by means of inhalation. These systems take advantage of the lung’s large surface area, thin epithelial layer, and rich blood supply to facilitate rapid and efficient absorption of medications. The pulmonary drug delivery systems market growth is attributed to the increasing burden of respiratory diseases and growing strategic initiatives by companies. However, regulatory issues associated with the approval of pulmonary drug delivery systems hinder the growth of the pulmonary drug delivery systems market.

Recently, various initiatives and measures have been taken to create awareness and educate people regarding respiratory diseases, prompting patients to access suitable medications and treatments for such conditions. Cipla has a public service initiative called Breathefree for people with chronic airway diseases. Berok Zindagi's program seeks to enable asthmatics to reach their true potential and lead lives that are unstoppable with the use of an inhaler. Berok Zindagi has been crafted as a tool to arm consumers with all the information they require to embrace inhalers without reluctance and confront the stigma associated with inhalation therapy. By using multilingual and multimedia educational resources to raise awareness about illnesses and inhalers, educators ensure patient counseling. Through the efforts of 600+ Breathefree Educators and 5600+ doctors, the Breathefree Clinic service serves over 1,25,000+ respiratory patients throughout India.

CDC’s National Asthma Control Program also provides funds for educating patients with asthma to receive education regarding their condition. Thus, such initiatives are likely to increase awareness about respiratory diseases, offering new opportunities for the growth of the pulmonary drug delivery systems market.

Distribution Channel-Based Insights

Based on distribution channel, the pulmonary drug delivery systems market is categorized into hospital pharmacies, retail pharmacies, and e-commerce. The hospital pharmacies segment held a significant pulmonary drug delivery systems market share in 2023. In addition, the e-commerce segment is expected to register the highest CAGR during the forecast period. Hospital pharmacies are specialized pharmacies integrated into healthcare centers such as hospitals, clinics, poison control centers, residential care facilities’ drug information centers, and drug dependency facility centers. Capacities to support the storage of extensive stocks, availability of various medicines on the spot, and reimbursement on the drugs purchased under healthcare plans are the primary benefits conferred by these pharmacies. Hospital pharmacies are not retail establishments; they typically provide medications for hospitalized patients. Therefore, they don’t provide prescription services to the public. Hence, the ease of availability of specialized therapeutics contributes to the inclination of patients toward hospital pharmacies, which is positively influencing the pulmonary drug delivery systems market growth.

End User-Based Insights

Based on end user, the pulmonary drug delivery systems market is categorized into hospitals & clinics and homecare. The hospitals & clinics segment held a significant pulmonary drug delivery systems market share in 2023. The homecare segment is estimated to register a higher CAGR during 2023–2031.

The US Food and Drug Administration, the World Health Organization, and the Centers for Disease Control and Prevention are among the primary and secondary sources referred to while preparing the pulmonary drug delivery systems market report.